证券日报网讯 10月31日晚间，威高血净发布公告称，公司正在筹划以发行股份的方式购买山东威高普 瑞医药包装有限公司（简称"威高普瑞"）100%股权（简称"本次交易"）。本次交易完成后，威高普瑞 将成为公司的全资子公司。根据《上市公司重大资产重组管理办法》等相关法律法规规定，经初步测 算，本次交易预计构成重大资产重组，构成关联交易。本次交易不会导致公司实际控制人的变更，不构 成重组上市。为了维护投资者利益，避免对公司股价造成重大影响，根据上海证券交易所的相关规定， 经公司申请，公司股票自2025年10月20日（星期一）开市起停牌。2025年10月31日，公司召开第二届董 事会第十七次会议，审议通过了《关于及其摘要的议案》等与本次交易相关的议案。根据相关规定，经 向上海证券交易所申请，公司股票将于2025年11月3日（星期一）开市起复牌。截至本公告披露日，本 次交易涉及的审计、评估等工作尚未完成，公司拟暂不召开审议本次交易的股东会。 （文章来源：证券日报） ...

Core Viewpoint - Weigao Group (01066.HK) announced a conditional sale agreement for Weigao Purui, aiming to enhance its stake in Weigao Xuejing and expand its overall business footprint and profitability through synergies [1] Group 1: Transaction Details - Weigao Xuejing will acquire 100% of Weigao Purui's shares, with the transaction price set at RMB 31.29 per share for the consideration shares issued to Weigao Purui's shareholders [1] - The number of consideration shares to be issued will be calculated based on the final transaction price divided by the issuance price per share [1] - Following the completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Xuejing, which may then become a non-wholly-owned subsidiary of the company [1] Group 2: Ownership and Financial Implications - As of the announcement date, the company holds a 23.53% stake in Weigao Xuejing [1] - The transaction is expected to increase the company's ownership in Weigao Xuejing and integrate the financial accounts of Weigao Purui and Weigao Xuejing into the company's financial statements [1] - The board believes that the transaction will create synergies between Weigao Purui and Weigao Xuejing, further expanding the company's overall business landscape and enhancing profitability [1]

Core Viewpoint - Weigao Group (01066.HK) announced a conditional sale agreement for Weigao Purui, aiming to enhance its stake in Weigao Xuejing and expand its overall business footprint and profitability through synergies [1] Group 1: Transaction Details - Weigao Xuejing will acquire 100% of Weigao Purui's shares, with the transaction price set at RMB 31.29 per share for the consideration shares issued to Weigao Purui's shareholders [1] - The number of consideration shares to be issued will be calculated based on the final transaction price divided by the issuance price per share [1] - Following the completion of this transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Xuejing, while Weigao Xuejing may become a non-wholly-owned subsidiary of the company [1] Group 2: Ownership and Financial Implications - As of the announcement date, the company holds a 23.53% stake in Weigao Xuejing, which is expected to increase post-transaction [1] - The financial accounts of Weigao Purui and Weigao Xuejing may be consolidated into the company's financial statements, enhancing overall business scale [1] - The board believes that the transaction will create synergies between Weigao Purui and Weigao Xuejing, leading to an expansion of the group's business landscape and improved profitability [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) plans to issue shares to acquire 100% equity of Weigao Puri from Weigao Co., Weihai Shengxi, and Weihai Ruiming, with the valuation and transaction price yet to be determined as the audit and assessment work is still ongoing [1] Group 1 - The acquisition will add pre-filled drug delivery systems and automatic safety drug delivery systems to the company's main business, expanding its product line into the pharmaceutical packaging sector [1] - Post-transaction, the company aims to leverage the technical accumulation and product layout of the target company to enhance its offerings in the pharmaceutical packaging field [1] - The collaboration is expected to synergize the company's hollow fiber filtration technology with the target company's extensive customer resources in biopharmaceuticals, enabling mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. from Weigao Co., Weihai Shengxi, and Weihai Ruiming [1] Group 1: Transaction Details - The company will resume trading on November 3, 2025, following the announcement of the share issuance for the acquisition [1] - The acquisition aims to integrate the target company's technological accumulation and product layout, expanding the product line into the pharmaceutical packaging sector [1] Group 2: Strategic Benefits - Post-transaction, the company expects to leverage its hollow fiber filtration technology alongside the target company's extensive customer resources in biopharmaceuticals [1] - This collaboration is anticipated to enhance both parties' product technology reserves and sales channels, focusing on the biopharmaceutical filter business and expanding into the upstream biopharmaceutical market [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. from Weigao Co., Weihe Shengxi, and Weihai Ruiming [1] Group 1: Transaction Details - The company will resume trading on November 3, 2025 [1] - The acquisition aims to integrate the target company's technological accumulation and product layout, expanding the product line into the pharmaceutical packaging sector [1] Group 2: Strategic Benefits - Post-transaction, the company can leverage its hollow fiber filtration technology alongside the target company's extensive customer resources in biopharmaceuticals [1] - This collaboration is expected to enhance both parties' product technology reserves and sales channels, focusing on the biopharmaceutical filter business and expanding into the upstream biopharmaceutical market [1]

山东威高血液净化制品股份有限公司董事会 关于本次交易信息公布前公司股票价格波动情况的说明 山东威高血液净化制品股份有限公司（以下简称"公司"）正在筹划以发行股 份的方式购买山东威高普瑞医药包装有限公司 100%股权（以下简称"本次交易"）。 因筹划本次交易，公司于 2025 年 10 月 18 日发布《山东威高血液净化制品股份 有限公司关于筹划发行股份购买资产暨关联交易事项的停牌公告》（公告编号： 2025-033），公司股票于 2025 年 10 月 20 日开市起停牌。根据相关规定，公司就本 次交易停牌前 20 个交易日内的股票价格波动情况进行了自查，该期间内公司股价涨 跌幅情况、同期上证指数及行业指数涨跌幅情况如下： | 项目 | 停牌前第 （2025 年 | 21 9 | 个交易日 月 11 日） | （2025 | 停牌前第 1 年10 月 | 交易日 17 日） | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | --- | | 股票收盘价（元/股） | | | 40.38 | | | 38.61 | -4.38% | | 上证指数（000001 ...

山东威高血液净化制品股份有限公司董事会 关于本次交易是否构成重大资产重组、关联交易及重组上市的 说明 本次交易的交易对方山东威高集团医用高分子制品股份有限公司、威海盛熙企 业管理咨询中心（有限合伙）和威海瑞明企业管理咨询合伙企业（有限合伙）均为 上市公司实际控制人陈学利控制的企业。根据《上海证券交易所股票上市规则》的 相关规定，本次交易构成关联交易。上市公司在召开董事会、股东会审议本次交易 时，关联董事、关联股东将回避表决。 三、本次交易不构成重组上市 本次交易前，上市公司实际控制人为陈学利；本次交易后，上市公司实际控制 人仍为陈学利，本次交易不会导致公司控制权变更。本次交易前三十六个月内，上 市公司的实际控制人未发生变更。因此，本次交易不构成《上市公司重大资产重组 管理办法》第十三条规定的重组上市情形。 特此说明。 山东威高血液净化制品股份有限公司董事会 2025 年 11 月 1 日 山东威高血液净化制品股份有限公司（以下简称"公司"或"上市公司"）正 在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司 100%股权（以下简称 "本次交易"）。经董事会审慎核查，就本次交易是否构成重大资产重组、关联交 ...

（摘要） 证券代码：603014 证券简称：威高血净 上市地：上海证券交易所 山东威高血液净化制品股份有限公司 发行股份购买资产暨关联交易预案 | 交易类型 | 交易对方 | | --- | --- | | | 山东威高集团医用高分子制品股份有限公司 | | 发行股份购买资产 | 威海盛熙企业管理咨询中心（有限合伙） | | | 威海瑞明企业管理咨询合伙企业（有限合伙） | 二〇二五年十月 声 明 本部分所述词语或简称与本预案摘要"释义"所述词语或简称具有相同含义。 一、上市公司声明 本公司及全体董事、高级管理人员保证本预案摘要内容的真实、准确、完整，对 本预案摘要的虚假记载、误导性陈述或者重大遗漏负相应的法律责任。 本公司控股股东、实际控制人、全体董事及高级管理人员承诺：如就本次交易所 披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或 者被中国证券监督管理委员会立案调查的，在形成调查结论以前，不转让在上市公司 拥有权益的股份，并于收到立案稽查通知的两个交易日内将暂停转让的书面申请和股 票账户提交上市公司董事会，由上市公司董事会代为向证券交易所和证券登记结算机 构申请锁定；未在两个交 ...

山东威高血液净化制品股份有限公司董事会 4、公司按照有关规定，制作了《内幕信息知情人登记表》，并编制了《重 大事项进程备忘录》，经相关人员签字确认。 5、公司根据《上市公司监管指引第 5 号——上市公司内幕信息知情人登记 管理制度》等相关规定，建立了内幕信息知情人档案，并将有关材料向上海证券 交易所进行报备。 综上，公司在本次交易中已根据相关法律、法规及规范性文件的规定，采取 了必要且充分的保密措施，制定了严格有效的保密制度，限定了相关敏感信息的 知悉范围，严格履行了本次交易信息在依法披露前的保密义务。 特此说明。 关于本次交易采取的保密措施及保密制度的说明 山东威高血液净化制品股份有限公司（以下简称"公司"）拟通过发行股份 方式购买山东威高普瑞医药包装有限公司 100%股权（以下简称"本次交易"）。 公司就本次交易采取了必要且充分的保密措施，制定了严格有效的保密制度， 现就关于本次交易采取的保密措施及保密制度情况具体说明如下： 1、公司严格控制内幕信息知情人范围，尽可能缩小知悉本次交易相关敏感 信息的人员范围。 2、公司对相关内幕信息知情人履行了保密和严禁内幕交易的告知义务，多 次告知内幕信息知情人员要严格 ...